Avery Dennison develops new products for pharmaceutical labeling

Avery Dennison develops new products for pharmaceutical labeling

The pandemic has made consumers pay more attention to health and wellness than ever before. This shift in thinking sparked greater interest and dependence on pharmaceuticals, nutraceuticals and the like.

The pharmaceutical brand industry has continued to see a surge in innovation, as new opportunities have the potential to change the entire landscape. For example, a smart label could help doctors monitor the progress of their patients. This is just one example.

Suppliers of label and package printing develop new products to meet customers’ demands for innovation. Avery Dennison has developed a dedicated portfolio of label materials – the Pharmaceutical and Healthcare Collection – for consumer healthcare and ethical pharmaceuticals. The products in the portfolio have been independently tested, meet a wide range of regulatory standards, and come with a robust commitment on component changes of up to 12 months.

In addition to the core pharmaceutical and healthcare collection, Avery Dennison offers several application-specific portfolios, including syringes, blood bags and cold chain and cryogenics.

Avery Dennison continuously strives to meet the “revolutionary” nature of innovation in this space. “From mobile medical apps and software that support the clinical decisions doctors make every day to artificial intelligence and machine learning, digital technology has driven a revolution in healthcare,” said Cory Keller, senior product manager, pharmaceuticals, Avery Dennison Label and Packaging Materials. “Digital health tools have the enormous potential to improve our ability to accurately diagnose and treat disease and to improve the delivery of health care for the individual. Digital health technologies use computing platforms, connectivity, software and sensors for health care and related uses. As digital health tools develops, it is likely to create new opportunities for intelligent pharma labeling solutions.”

See also  10 apps to help you keep your New Year's resolutions

Counterfeiting is also a major concern for pharmaceutical brands. Avery Dennison has developed a broad portfolio of tamper-proof and anti-counterfeit label solutions, including destructive labels, box damage films and voidable labels, to help curb this rising trend.

“Counterfeit medicines are a major global problem, compromising patient safety and brand reputation,” explains Keller. “Tamping-evident and void labels are the most affordable and popular solutions for pharmaceutical companies that want to protect their products from counterfeiting, although there are more exotic covert solutions, such as luminescent materials.”

Pharmaceutical labeling has been a major focus for Avery Dennison. Because of the critical nature of this segment, Avery Dennison has prioritized material procurement for pharma applications, says Keller. “Like the wider label market, paper supply is a major challenge for pharmaceutical labelling. Through the raw material supply challenges of recent years, Avery Dennison has prioritized the Pharmaceutical and Healthcare Collection to minimize supply disruptions, as these materials are often used in critical life-saving medicines and medical devices.”

The company’s acquisition of Smartrac has also positioned it to continue to offer technologies for this market.

“The use cases for RFID in pharmaceuticals and healthcare are very compelling and are leading to increased adoption,” comments Keller. “An example of RFID in use today is with Kit Check, which partnered with Avery Dennison Smartrac to add RFID tags to medicine packaging that goes to hospitals, helping to improve patient safety by enabling more accurate tracking and authentication of drugs throughout the supply chain. It also eliminates the need for cost- and labor-intensive in-house drug labeling at hundreds of hospitals.”

See also  Best Sports Betting Apps for Super Bowl 2023

Avery Dennison has emphasized the use of smart technology over the years. While not pharma specific, the company is marketing atma.io, which it says is a leading connected product cloud. This technology platform has the ability to unlock the power of connected products by assigning unique digital IDs at the item level, and provide end-to-end transparency by tracking, storing and managing all the events associated with each individual product – from source to consumer and beyond to enable circularity.

As with its other portfolios, sustainability has also driven product development in pharmaceutical labeling. As Keller notes, most major pharmaceutical companies now have 2025-2030 sustainability goals, which include a packaging element.

“For example, Pfizer’s Sustainable Packaging Team works with brand managers and packaging designers to minimize materials used, maximize the use of recycled or renewable materials, avoid harmful materials such as PVC, source materials from certified, responsibly managed forests, and optimize the number of products per package,” says Keller . “Avery Dennison’s Pharmaceutical and Healthcare Collection includes paper bottles with Forest Stewardship Council (FSC) certification and film constructions that have Association of Plastics Recyclers (APR) recognition for HDPE recycling to help pharmaceutical companies meet their sustainability goals.”

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *